Publicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (24)

2022

  1. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  2. SARS-CoV-2 vaccine excipients polyethylene glycol and trometamol do not induce mast cell degranulation, in an in vitro model for non-IgE-mediated hypersensitivity

    Frontiers in Allergy, Vol. 3

2021

  1. Author Correction: MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia (Scientific Reports, (2018), 8, 1, (11628), 10.1038/s41598-018-29965-8)

    Scientific Reports

  2. Erratum: MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis (Journal of Immunology (2021) 206 (2277-2289) DOI: 10.4049/jimmunol.2001211)

    Journal of Immunology

  3. MYO1F regulates IgE and MRGPRX2-dependent mast cell exocytosis

    Journal of Immunology, Vol. 206, Núm. 10, pp. 2277-2289

  4. The multifaceted mas‐related g protein‐coupled receptor member x2 in allergic diseases and beyond

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2019

  1. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  2. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria giménez

    Journal of Investigational Allergology and Clinical Immunology, Vol. 29, Núm. 5, pp. 338-348

2018

  1. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe

    Rhinology, Vol. 55, Núm. 1, pp. 34-38

  2. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Comparable actions of omalizumab on mast cells and basophils

    Clinical and Experimental Allergy, Vol. 46, Núm. 1, pp. 92-102

2015

  1. Management of urticaria: Not too complicated, not too simple

    Clinical and Experimental Allergy, Vol. 45, Núm. 4, pp. 731-743

2013

  1. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain

    Pediatric Allergy and Immunology, Vol. 24, Núm. 7, pp. 678-684

  2. ESPRINT-15 questionnaire (Spanish version): Reference values according to disease severity using both the original and the modified ARIA classifications

    Journal of Investigational Allergology and Clinical Immunology, Vol. 23, Núm. 1, pp. 14-19

2012

  1. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: The PEDRIAL study

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 67, Núm. 11, pp. 1437-1442

2011

  1. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study

    Pediatric Allergy and Immunology, Vol. 22, Núm. 4, pp. 388-392

2010

  1. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort Study

    Rhinology, Vol. 48, Núm. 2, pp. 201-205

2009

  1. Allergic conjunctivitis and H1 antihistamines

    Journal of Investigational Allergology and Clinical Immunology, Vol. 19, Núm. SUPPL. 1, pp. 11-18

  2. Allergic rhinitis and school performance

    Journal of Investigational Allergology and Clinical Immunology, Vol. 19, Núm. SUPPL. 1, pp. 32-39